Valuation as at 2026-08-14 · see also the ASX 300 Most Undervalued screen
About Cochlear Limited
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor and Baha implant; and accessories, such as wireless devices and Nucleus water-safe accessories.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Cochlear Limited COH.AX
Healthcare · Medical Devices
Cochlear Limited's price & financial trends
Annual reporting periods — this market does not have reliable quarterly data on Yahoo (either it isn't required, or coverage is incomplete), so annual is the most granular consistent series across free cash flow and dividends.
Data as at 2026-08-14
Share price · last 2 years
Earnings per share (diluted) Per year
Free cash flow Per year
Dividend per share Per year
Value investing scale · Buffett · Dalio · Graham
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | -7.5% | -5.0% | -2.5% |
| Terminal growth | 2.5% | 2.5% | 2.5% |
| WACC (discount rate) | 8.70% | 7.70% | 6.70% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 4.80% + 0.50 × 6.00% = 7.80% · WACC = weighted by 97%/3% capital structure
These numbers come from running Cochlear Limited's cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or COH.AX's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with COH.AX →
More ASX stocks we've valued
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Computed on 2026-08-14 from Yahoo Finance data, using the same engine as the full DCF tool and the ASX 300 Most Undervalued screen. Every figure above is a point-in-time snapshot of that date — change any assumption yourself in the interactive tool for a live one.
Frequently asked questions
Is Cochlear Limited (COH.AX) undervalued?
The Base-case DCF estimates intrinsic value at $25.37 vs a price of $132.38 on 2026-08-14 — a -80.8% margin, so the Base case reads overvalued. This is a mechanical output, not advice.